Regado Biosciences, Inc.
http://www.regadobio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Regado Biosciences, Inc.
Takeda Adds To Its Celiac Pipeline With Innate-Discovered Antibodies
Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Asia Deal Watch: Astellas Acquires Global Rights To KaliVir Oncolytic Virus Candidate
Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice